It is was explored for its broad-spectrum anticancer activity in >10 clinical trials (clinicaltrials.gov), including estrogen receptor (ER) +ve and herceptine (HER) +ve breast cancer conditions [13,14]. This evidence concerns the gene ESR1 and breast carcinoma.